摘要
背景:奥罗拉激酶在肿瘤治疗中是可行的靶点。 目的:探讨人肝癌细胞对alisertib(ALS)的蛋白质组学反应和确定ALS的分子靶点,我们研究了ALS影响HepG2细胞的增殖,细胞周期,细胞自噬,细胞凋亡和化疗敏感性。 方法:基于定量蛋白质组学用氨基酸在细胞培养(SILAC)研究稳定的同位素标记,评估ALS蛋白质组学反应。用流式细胞仪检测细胞周期分布和细胞凋亡,流式细胞术和共聚焦显微镜测定自噬。 结果:我们的SILAC蛋白质组研究表明ALS调节914蛋白的表达,上调407分子和507分子和下调HepG2细胞。信号网络分析(IPA)和KEGG通路分析,发现ALS调节146和32信号通路,分别与细胞的存活、细胞程序性死亡和营养能量代谢相关。随后的验证实验表明,通过调节关键的细胞周期调控因子的表达,ALS明显地阻滞G2 / M期的HepG2细胞,并导致非整倍体的积累。 ALS通过雷帕霉素(mTOR)信号通路磷脂酰肌醇3-激酶(PI3K)/蛋白激酶B(Akt)/哺乳类动物靶点,诱导了依赖浓度和时间的标记的自噬。自噬的抑制促进了ALS的促凋亡作用,表明ALS诱导的自噬的细胞保护作用。ALS增加HepG2细胞对顺铂和阿霉素的化疗敏感性。 结论:通过PI3K/Akt/mTOR-介导通路,ALS诱导HepG2细胞自噬和细胞周期阻滞。抑制自噬可促进ALS的抗癌作用和提高肝癌HepG2细胞的化疗敏感性。
关键词: 肝癌,HepG2细胞,奥罗拉激酶A,alisertib,细胞周期,程序性细胞死亡,SILAC,蛋白质组学。
图形摘要
Current Cancer Drug Targets
Title:Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells
Volume: 17 Issue: 4
关键词: 肝癌,HepG2细胞,奥罗拉激酶A,alisertib,细胞周期,程序性细胞死亡,SILAC,蛋白质组学。
摘要: Background: Aurora A kinase represent a feasible target in cancer therapy.
Objective: To evaluate the proteomic response of human liver carcinoma cells to alisertib (ALS) and identify the molecular targets of ALS, we examined the effects of ALS on the proliferation, cell cycle, autophagy, apoptosis, and chemosensitivity in HepG2 cells. Method: The stable-isotope labeling by amino acids in cell culture (SILAC) based quantitative proteomic study was performed to evaluate the proteomic response to ALS. Cell cycle distribution and apoptosis were assessed using flow cytometry and autophagy was determined using flow cytometry and confocal microscopy. Results: Our SILAC proteomic study showed that ALS regulated the expression of 914 proteins, with 407 molecules being up-regulated and 507 molecules being down-regulated in HepG2 cells. Ingenuity pathway analysis (IPA) and KEGG pathway analysis identified 146 and 32 signaling pathways were regulated by ALS, respectively, which were associated with cell survival, programmed cell death, and nutrition-energy metabolism. Subsequently, the verification experiments showed that ALS remarkably arrested HepG2 cells in G2/M phase and led to an accumulation of aneuploidy via regulating the expression of key cell cycle regulators. ALS induced a marked autophagy in a concentration- and time-dependent manner via the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling pathway. Autophagy inhibition promoted the pro-apoptotic effect of ALS, indicating a cyto-protective role of ALS-induced autophagy. ALS increased the chemosensitivity of HepG2 cells to cisplatin and doxorubicin. Conclusion: Taken together, ALS induces autophagy and cell cycle arrest in HepG2 cells via PI3K/Akt/mTOR-mediated pathway. Autophagy inhibition may promote the anticancer effect of ALS and sensitize the chemotherapy in HepG2 cells.Export Options
About this article
Cite this article as:
Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells, Current Cancer Drug Targets 2017; 17 (4) . https://dx.doi.org/10.2174/1568009616666160630182344
DOI https://dx.doi.org/10.2174/1568009616666160630182344 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Interactions of Metal Ions with DNA, Its Constituents and Derivatives, which may be Relevant for Anticancer Research
Current Topics in Medicinal Chemistry Targeting Vesicle Trafficking: An Important Approach to Cancer Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery Drugs Interfering with Apoptosis in Breast Cancer
Current Pharmaceutical Design Preparation and Characterization of Stattic-Loaded Albumin Nanoparticles for Antimetastatic Cancer Treatment
Drug Delivery Letters Bugs and Drugs: Oncolytic Virotherapy in Combination with Chemotherapy
Current Pharmaceutical Biotechnology Translational Pharmacology in Aging Men with Benign Prostatic Hyperplasia: Molecular and Clinical Approaches to Alpha1-Adrenoceptors
Current Aging Science MicroRNA-34 Family, Mechanisms of Action in Cancer: A Review
Current Cancer Drug Targets Infection and Malignancy Risk in Patients Treated with TNF Inhibitors for Immune-Mediated Inflammatory Diseases
Current Drug Safety Liposomal Doxorubicin Delivery Systems: Effects of Formulation and Processing Parameters on Drug Loading and Release Behavior
Current Drug Delivery Alzheimer’s Disease and Environmental Exposure to Lead: The Epidemiologic Evidence and Potential Role of Epigenetics
Current Alzheimer Research Controlled Releases of FGF-2 and Paclitaxel from Chitosan Hydrogels and their Subsequent Effects on Wound Repair, Angiogenesis, and Tumor Growth
Current Drug Delivery The Human L1 Element: A Potential Biomarker in Cancer Prognosis, Current Status and Future Directions
Current Molecular Medicine microRNA, Cancer and Cancer Chemoprevention
Current Molecular Pharmacology Development of Amino Acid-Based Radiopharmaceuticals for Tumor Imaging
Mini-Reviews in Medicinal Chemistry Radiogenetic Therapy: Strategies to Overcome Tumor Resistance
Current Pharmaceutical Design Fentanyl for Breakthrough Cancer Pain: Where are We?
Reviews on Recent Clinical Trials Reactive Oxygen Species in Pathogenesis of Atherosclerosis
Current Pharmaceutical Design Targeting Sphingosine-1-Phosphate Receptors in Cancer
Anti-Cancer Agents in Medicinal Chemistry The Production and Role of Gastrin-17 and Gastrin-17-Gly in Gastrointestinal Cancers
Protein & Peptide Letters Omega-3 Fatty Acid Treatment Combined with Chemotherapy to Prevent Toxicity, Drug Resistance, and Metastasis in Cancer
Current Drug Targets